And hot on the tail of Repatha is a RNA interference (RNAi) drug from Alnylam/The Medicines Company called inclisiran that reduces PCSK9 by RNAi instead of antibody-mediated like Repatha. Needs to be given by injection like Repatha but can be dosed less frequently (43% reduction in LDL after 180 days with single injection). Repatha is given once or twice a month. Inclisiran is just now entering Phase 3, but could be a less expensive and more convenient way to achieve the same result as Repatha. 

https://endpts.com/medicines-co-alnylam-prepare-to-throw-the-dice-on-a-late-stage-effort-to-leapfrog-pcsk9-giants

To avoid being completely off topic, I will add that Resverlogix may be a leader in the BET inhibitor field now, but one is only a leader for so long until getting knocked off the pedestal. I sure hope Resverlogix is the first to market with a BET inhibitor and if that happens I hope that Zenith joins them shortly thereafter! 

BearDownAZ